[A23-30] Tremelimumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V
Last updated 11.08.2023
Project no.:
A23-30
Commission:
Commission awarded on 03.04.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
First-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma
- With Child-Pugh A or no hepatic cirrhosis: added benefit not proven
- With Child-Pugh B: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2023-07-03.
| Project no. | Title | Status |
|---|---|---|
| A23-29 | Tremelimumab (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-87 | Durvalumab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-86 | Durvalumab (first-line in combination with carboplatin and paclitaxel, maintenance in combination with olaparib; endometrial cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-138 | Durvalumab (HCC) – Benefit assessment according to §35a Social Code Book V | Commission completed |